SEATTLE, WASHINGTON--TapImmune, Inc. (OTCBB: TPIV), provides an update on the status of its PolyStartTM vaccine technology platform in light of recent global concerns regarding pandemic infections and emerging viral threats such as Ebola and Enterovirus.
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT) (http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that Sanjiv S. Agarwala, MD, of St. Luke's University Hospital and Professor of Medicine at Temple University will present data on its investigational new drug PV-10 for the treatment of melanoma at the 11th International Congress of the Society for Melanoma Research in Zurich, Switzerland.
New York, NY--Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the issuance of approximately 10.1 million of its shares of common stock pursuant to the exercise of A-Warrants originally issued in connection with private placements that closed in May and June 2014.
KNOXVILLE, TN--Provectus Biopharmaceuticals, Inc.(NYSE MKT: PVCT)(http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company (“Provectus”), announced today that it has retainedINC Research, a leading, global Phase I to IV contract research organization, to conduct an FDA due diligence audit of its regulatory documents for PH-10 and PV-10.
HAIFA, Israel--Pluristem Therapeutics Inc. (PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapy products, announced today that its European Patent No. EP2200622, titled, "ADHERENT CELLS FROM ADIPOSE OR PLACENTA TISSUES AND USE THEREOF IN THERAPY", was upheld by the European Patent Office in amended form, affirming its validity.
Pluristem's patent went through Opposition Proceedings before the Opposition Division of the European Patent Office, as a result of a challenge from a cell therapy company.
Healthcare valuation and consulting experts seeking help in navigating the treacherous regulatory landscape of healthcare can’t afford to miss an in-depth symposium this December presented by the National Association of Certified Valuators and Analysts™ (NACVA®) and the Consultants’ Training Institute™ (CTI™). The Advanced Healthcare Valuation and Consulting Symposium will be held December 12–13, 2014, in San Diego, CA at the Solamar Hotel.
Vienna, VA--CEL-SCI Corporation(NYSE MKT: CVM)today announced that during the month of September the Company enrolled 16 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection).
ROCHESTER, NY--Four years ago, the Institute of Medicine recommended the Department of Health and Human Services promote the use of clinical decision support tools to ensure doctors quickly and accurately detect and diagnose bioterrorism and infectious disease outbreaks.
LOS ANGELES - Surveying patients with traumatic brain injuries, a group of Los Angeles Biomedical Research Institute (LA BioMed) researchers reported today that they found those who tested positive for THC, the active ingredient in marijuana, were more likely to survive than those who tested negative for the illicit substance.
MORGANTOWN, W.V., and Schileren, Switzerland October 2, 2014 -- Protea Biosciences Group, Inc. (OTCQB:PRGB) and InSphero AG jointly announced today an update from their collaboration focused on mass spectrometry imaging of InSphero’s 3D InSight™ microtissues.